Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA

He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the field in general, including what orforglipron might mean for the oral therapy space and why Metsera believes in an oral peptide.